Everolimus suppresses the cell viability of osteoclasts but not preosteoblasts in vitro. RAW 246.7 cells (a) were differentiated with RANKL for 5 days and hMSC (b) with an osteoblast differentiation cocktail for 8 days before the addition of everolimus for 2 days. The CellTiter-Blue® assay was then performed to assess viability. Data were analyzed using one-way ANOVA and the Bonferroni posttest and are shown as mean ± SD (*** p